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Abstract: Introduction: Nutraceutical is a term applied for a plethora of products ranging from 
isolated nutrients, herbal products to dietary supplements and recently, the interest for a nutraceutical approach to lipid 
and metabolic disorders is growing. Patients with metabolic conditions seem to appreciate a therapeutic management that 
does not involve drug treatment, particularly for the side effects due to statins, a class of drug used for lipid disorders. 
Statins directly induce skeletal muscle injury and in elderly patients, under polytherapy treatments, this risk relies to an 
increase of adverse drug reactions due to drug interactions. 
Case Description: Herein we report a 70-year-old woman under polytherapy, who develops rhabdomyolysis after starting 
the administration of a dietary supplement containing monacolin K. Using the Drug Interaction Probability Scale we 
postulated that rhabdomyolysis was possibly related to a drug interaction between sertraline, rosuvastatin and monacolin 
K. These treatments were discontinued leading to a remission of both clinical symptoms and biochemical parameters. 
Conclusion: This case report highlights how pharmacological treatment must be periodically reassessed, since elderly 
people could take drugs by themselves when they don’t need. 
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INTRODUCTION 
 Nutraceutical is a term applied for a plethora of products 
ranging from functional foods (i.e. products that beneficially 
affect one or more target functions in the body, beyond 
adequate nutritional effects), food supplements (i.e. 
concentrated source of nutrients or other substances with a 
nutritional or physiological effect) to dietary foods (i.e. 
complete foods with a standard nutrient formulation which 
may constitute the only source of nourishment for a designed 
person), able to provide health benefits [1]. 
 Even if their use is increasing among the general 
population, very low data have been published concerning 
their safety. In a recent paper, Geller and coworkers [2] 
evaluating surveillance data from 63 emergency departments 
in the United States obtained from 2004 through 2013, 
estimated that 23,005 emergency department visits/year were 
attributed to adverse events related to dietary supplements. 
 The risk of an adverse event is related to age of the 
patient but also to the co administered drug. In fact, recently 
Felix et al. [3], reported that the potential for the  
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development of adverse drug reactions during the treatment 
with dietary supplements can be amplified in elderly patients 
or those taking multiple prescription drugs; this may be 
related with the development of drug interactions (DIs) 
involving all the phases of the pharmacokinetic of each drug. 
 It has been reported that hypolipidemic supplements, 
such as monacolin K, are also able to evocate myopathy and 
rhabdomyolysis [4]. Here we report a case where a 
nutraceutical (Armolipid plus®) reinforced drug side effects 
inducing rhabdomyolysis by DI in an elderly patient. 
CASE SUMMARY 
 On 16th October 2013, a 70-year-old woman lamented 
acute muscular pain, with muscular weakness and reduced 
mobilization of limbs. Clinical examination performed by 
orthopedist excluded bone damage and neurological failure. 
Her clinical history revealed the presence of 
hypercholesterolemia, hypothyroidism, blood hypertension, 
Parkinson’s disease and depression, for that she was treated 
with rosuvastatin (5 mg o.d.; daily dose 5 mg), levothyroxine 
(100 mcg o.d.; daily dose 100 mcg), perindopril plus 
indapamide (2.5/0.625 mg o.d.; daily dose perindopril 2.5 
mg and indapamide 0.625 mg) pramipexole (0.18 mg 1 and 
½ tablets in the morning and two tablets at bedtime; daily 
dose 0.63 mg) and sertraline (150 mg o.d.; daily dose 150 
mg), respectively. Biochemical laboratory parameters3 days 
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later the admission to hospital (19th October 2013) revealed 
the presence of muscular failure (Table 1). Cardiac failure 
was excluded. The patient reported that about 15 days before 
the admission she started one tablet/day of an oral dietary 
supplement containing natural substances: policosanol (10 
mg/table), red yeast rice (200 mg/table), berberine (588 
mg/table), folic acid (200 mcg/table) coenzyme Q10 (2 
mg/table) and astaxanthin (0.5 mg/table). 
 Pharmacological assessment revealed the possible 
relationship among sertraline, rosuvastatin and red yeast rice 
(present in the dietary supplement). Using the Drug 
Interaction Probability Scale (DIPS) [5], we estimated that 
the DI among the active ingredients mentioned above, was 
probably involved in the development of rhabdomyolysis 
(DIPS score: 5). Therefore both rosuvastatin and the dietary 
supplement were discontinued, while sertraline was changed 
to escitalopram (10 mg o.d.; daily dose 10 mg) because it 
shows a low risk of drug interactions. One month later (29th 
November), during the follow-up, clinical and laboratory 
finding revealed a complete remission of both, clinical 
symptoms and biochemical parameters (see Table 1), but 
documented an increase in blood lipid plasma levels (total 
cholesterol: 285 mg/dL, normal values < 200 mg/dL; LDL 
cholesterol 142 mg/dL, normal values: < 100 mg/dL; HDL 
cholesterol 46 mg/dL, normal values > 45 mg/dL), therefore 
rosuvastatin (5 mg o.d.; daily dose 5 mg) was added. During 
the follow-up performed about 3 months later (06th March 
2014), no symptoms of depression appeared (Geriatric 
Depression Scale score 8/30), plasma cholesterol levels were 
in normal range (total cholesterol: 198 mg/dL; LDL 
cholesterol 99 mg/dL), without increase in rhabdomyolysis 
markers (Creatinine Phosphokinase: 84 IU/L; Lactate 
Dehydrogenase 202 IU/L; Aspartate Aminotransferase 29 
IU/L; Myoglobin 97 mcg/L). At the time of writing 
(November 2015, about two years later), no adverse drug 
reactions appeared. 
DISCUSSION 
 In this case, we report the development of 
rhabdomyolysis possibly related to a drug-nutraceutical 
interaction. Previously, we documented the development of 
generalized dermatitis and itch induced by a possible drug-
food interaction [6], moreover, we also reported that both 
sertraline and rosuvastatin are able to induce rhabdomyolysis 
[7, 8]. 
 In our patient, the co-administration of sertraline (150 
mg/day), rosuvastatin (5 mg/day) and of dietary 
supplement (1 table/day) containing red yeast rice induced 
the development of rhabdomyolysis. 
 Since benefits of statins are well documented [9], 
myopathy or rhabdomyolysis, have been associated with the 
use of statins; this effect is dose-related [10] and could be 
associated with pharmacokinetic interactions [8]. 
 On the other hand, the development of myopathy and 
rhabdomyolysis was also described in patients treated with 
monacolin K [4]. It is worth to note that red yeast rice contains 
monacolin K that has the identical biochemical/pharmacological 
action of lovastatin and is able per se to induce rhabdomyolysis 
[11, 12]. 
 Moreover, recently Philibert et al., [13] evaluating the 
French national pharmacovigilance database and in scientific 
literature, documented the development of muscular disorders in 
patients treated with monacolin K. 
 Even if yeast rice and rosuvastatin, have a direct effect on 
skeletal muscle tissue, other drugs such as benzodiazepines, 
antihistamines, barbiturates and antidepressants, are also able to 
predispose patients to the development of rhabdomyolysis [14]. 
 In the present case, our patient received a treatment with 
Selective Serotonin-Reuptake Inhibitors (SSRIs). Labotz and 
coworkers [15] reported the development of rhabdomyolysis in 
three patients treated with SSRIs after performing 15 sets of 15 
repetitions of maximal eccentric contractions of the elbow 
flexors, suggesting that SSRIs may represent a predisposing 
factor to muscle injury after eccentric exercise. Moreover, 
Gareri and co-workers [7] reported a 71-year-old woman with 
co-morbidity that developed rhabdomyolysis after the 
administration of sertraline (50 mg/day), supporting a role of 
sertraline in the development of this ADR probably related to 
genetic factor (e.g. Genetic defects of sertraline demethylation 
and/or P-glycoprotein binding). 
 Finally, the development of rhabdomyolysis may also be 
related to drug overuse. In fact, in a retrospective study Wilson 
et al., [16] documented the development of acute muscle injury 
in patients who ingested larger quantities of venlafaxine (mean 
2800 mg/day). 
 However, the development of rhabdomyolysis was also 
documented in a 21-year-old woman treated with low dosages 
of venlafaxine (37.5 mg/day) [17]. 
Table 1. Biochemical laboratory parameters recorded in a 70-year-old woman at the time of the first examination (16th October 
2013), at the time of the hospital admission (19th October 2013) and one month after the discontinuation of rosuvastatin 
and yeast rice, and the change of sertraline with escitalopram (29th November 2013). 
 
Biomarkers 16th October 19 th October  29th November Normal Range 
Creatinine Phosphokinase 82 4.800 85 0-180 IU/L 
Lactate Dehydrogenase 197 880 208 240-480 IU/L 
Aspartate Aminotransferase 28 255 29 0-30 IU/L 
Alanine Aminotransferase 22 80 31 0-34 IU/L 
Myoglobin 98 1000 101 <106 mcg/L 
Troponin I - 0.09 - <0.013 mcg/L 
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 In our patient, we can exclude a role of exercise as a factor 
able to increase the risk of rhabdomyolysis. Furthermore we 
cannot rule-out that this ADR might be related to genetic 
factors, involving the absorption and the metabolism and the of 
the drugs (e.g. cytochrome P450 and P-glycoprotein 
polymorphisms) [18]. However, we did not perform the 
therapeutic drug monitoring of drugs therefore we cannot 
exclude a drug overuse, and this represents a limit of this case, 
even if the patient and her parents referred to the use of standard 
dosage of each drug. 
 The discontinuation of both rosuvastatin and dietary 
supplement and the change of sertraline to escitalopram 
induced the complete remission of the clinical symptoms, and 
using the DIPS scale we postulated that a DI probable induced 
the development of rhabdomyolysis. 
 Although, nutraceuticals are over-the-counter drugs, without 
doubt they are not less dangerous than others due to their 
pharmacokinetic and pharmacodynamic interactions and our 
patient reported that she was taking the dietary supplement 
without her physician’s consultation. The present case is 
indicative for an inappropriate use of a dietary supplement to 
whoever was already under rosuvastatin and sertraline 
treatments. 
 The type of study, case report, represents another limit of 
this presentation and post-marketing drug safety surveillance 
data (e.g. voluntary spontaneous reports of adverse events from 
consumers and health care professionals) are necessary to 
validate this observation. However, we think that a surveillance 
system for a closer monitoring of the safety of nutraceutical 
substances may be useful to evaluate their safety in particular 
types of patients, i.e. elderly and patients in poly-therapy. 
 This case report highlights how pharmacological treatment 
must be periodically reassessed, since elderly people could take 
drugs by themselves when they do not need them. The 
reassessing of the therapy could also improve elderly patient’s 
psychological comfort, their quality of life and costs for their 
assistance. In fact, in agreement with our previously reports, the 
development of ADRs due to an inappropriate use, is an alert 
for physicians/pharmacists in order to carefully evaluate the co-
administration of drugs and dietary supplements [19]. This 
concern is particularly important for elderly people, who often 
take a relevant daily number of drugs. 
CONFLICT OF INTEREST 
 The authors confirm that this article content has no conflict 
of interest. 
ACKNOWLEDGEMENTS 
 The authors thank Domenico Sturino for careful English 
review of the manuscript. 
PATIENT’S CONSENT 
 Declared none. 
REFERENCES 
[1] Georgiou NA, Garssen J, Witkamp RF. Pharma-nutrition interface: The 
gap is narrowing. Eur J Pharmacol 2011; 651(1-3): 1-8. 
[2] Geller AI, Shehab N, Weidle NJ, et al. Emergency department visits for 
adverse events related to dietary supplements. New Engl J Med 2015; 
373(16): 1531-40. 
[3] Felix TM, Karpa KD, Lewis PR. Adverse effects of common drugs: 
dietary supplements. FP Essen 2015; 436: 31-40. 
[4] Lee CL, Hung YP, Hsu YW, Pan TM. Monascin and ankaflavin have 
more anti-atherosclerosis effect and less side effect involving increasing 
creatinine phosphokinase activity than monacolin K under the same 
dosages. J Agric Food Chem 2013; 61(1): 143-50. 
[5] Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate 
drug interaction cases. Ann Pharmacoth 2007; 41(4): 674-80. 
[6] Gallelli L, De Fazio S, Corace E, De Sarro G, Garcia CS, De Fazio P. 
Generalised urticaria in a young woman treated with clomipramine and 
after ingestion of codfish. Pharmacopsychiatry 2006; 39(4): 154-6. 
[7] Gareri P, Segura-Garcia C, De Fazio P, De Fazio S, De Sarro G. 
Sertraline-induced rhabdomyolysis in an elderly patient with dementia 
and comorbidities. Ann Pharmacother 2009; 43(7): 1354-9. 
[8] Gallelli L, Ferraro M, Spagnuolo V, Rende P, Mauro GF, De Sarro G. 
Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 
saturation. Drug Metabol Drug Interact 2009; 24(1): 83-7. 
[9] LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary 
disease - A meta-analysis of randomized controlled trials. Jama-J Am 
Med Assoc 1999; 282(24): 2340-46. 
[10] Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy 
with statin therapy in high-risk patients. Arch Intern Med 2003; 163(5): 
553-64. 
[11] Rhabdomyolysis linked to Chinese red yeast rice. Prescrire international 
2008; 17(94): 64. 
[12] Mastaglia FL, Needham M. Update on toxic myopathies. Curr Neurol 
Neurosci 2012; 12(1): 54-61. 
[13] Philibert C, Bres V, Jean-Pastor MJ, et al. [Read yeast rice induced 
muscular injuries: analysis of french pharmacovigilance database and 
literature review]. Therapie 2015; 15: 80. 
[14] Curry SC, Chang D, Connor D. Drug- and toxin-induced 
rhabdomyolysis. Ann Emerg Med 1989; 18(10): 1068-84. 
[15] Labotz M, Wolff TK, Nakasone KT, Kimura IF, Hetzler RK, Nichols 
AW. Selective serotonin reuptake inhibitors and rhabdomyolysis after 
eccentric exercise. Med Sci Sports Exerc 2006; 38(9): 1539-42. 
[16] Wilson AD, Howell C, Waring WS. Venlafaxine ingestion is associated 
with rhabdomyolysis in adults: a case series. The Journal of 
toxicological sciences 2007; 32(1): 97-101. 
[17] Huang SS, Yang HY, Lin YC, Chan CH. Low-dose venlafaxine-
induced severe rhabdomyolysis: a case report. Gen Hosp Psychiatry 
2012; 34(4): 436 e5-7. 
[18] Gallelli L, Gallelli G, Codamo G, et al. Recognizing severe Adverse 
Drug Reactions: two case reports after switching therapies to the same 
generic company. Curr Drug Saf 2015; 10(3): 51. 
[19] Gallelli L, Staltari O, Palleria C, Di Mizio G, De Sarro G, Caroleo B. A 
case of adverse drug reaction induced by dispensing error. J Forensic 
Leg Med 2012; 19(8): 497-8. 
 
 
 
 
 
Received: November 13, 2015 Revised: January 18, 2016 Accepted: January 23, 2016 
 
DISCLAIMER: The above article has been published in Epub (ahead of print) on the basis of the materials provided by the author. The Editorial Department 
reserves the right to make minor modifications for further improvement of the manuscript. 
 
 
 
PMID: 26830519 
